Comparing studies for cost effectiveness of screening

Ehlers and colleagues conclude from their long term modelling study that screening men aged 65 for abdominal aortic aneurysm is not cost effective. This conclusion conflicts with that of the 10 year follow-up of the randomised Multicentre Aneurysm Screening Study (MASS), our detailed long term modelling based on individual patient data in MASS, and other recent modelling studies.

To try to understand the reasons for the difference, we substituted the unit costs and parameter estimates provided by Ehlers into our model based on MASS. Although the cost per quality adjusted life year (QALY) increased from our original estimate of £3000 to around £6000, it does not begin to approach their figure of £43 000. So there must be other explanations, such as the structure or assumptions of their model, which cannot be investigated without further information from the authors.

Their cost effectiveness estimate is implausible. From observed data in MASS, we showed that cost effectiveness after 10 years was £9400 per QALY. Cost effectiveness will improve when considered over the longer term, since costs are generally up front while benefit accrues over time. But Ehlers and colleagues’ estimate of lifetime cost effectiveness is worse than that which we have already observed after 10 years. Moreover, they present the modelled number of deaths related to abdominal aortic aneurysm that accrue as a screening programme is launched, and claim that a net reduction is not reached until after nine years. Rerunning this analysis based on the data observed in MASS shows that benefit is seen after two years.

Ehlers and colleagues’ hypothetical modelling does not agree with the data observed in the MASS trial, which provides most of the worldwide randomised evidence. If one had to choose the basis on which to make policy decisions, real data are surely preferred.

Notes

1 Ehlers and colleagues conclude from their long term modelling study that screening men aged 65 for abdominal aortic aneurysm is not cost effective. This conclusion conflicts with that of the 10 year follow-up of the randomised Multicentre Aneurysm Screening Study (MASS), our detailed long term modelling based on individual patient data in MASS, and other recent modelling studies.

2 Cost effectiveness will improve when considered over the longer term, since costs are generally up front while benefit accrues over time. But Ehlers and colleagues’ estimate of lifetime cost effectiveness is worse than that which we have already observed after 10 years. Moreover, they present the modelled number of deaths related to abdominal aortic aneurysm that accrue as a screening programme is launched, and claim that a net reduction is not reached until after nine years. Rerunning this analysis based on the data observed in MASS shows that benefit is seen after two years.

3 Cost effectiveness after 10 years was £9400 per QALY. Cost effectiveness will improve when considered over the longer term, since costs are generally up front while benefit accrues over time. But Ehlers and colleagues’ estimate of lifetime cost effectiveness is worse than that which we have already observed after 10 years. Moreover, they present the modelled number of deaths related to abdominal aortic aneurysm that accrue as a screening programme is launched, and claim that a net reduction is not reached until after nine years. Rerunning this analysis based on the data observed in MASS shows that benefit is seen after two years.
Footnotes

• Competing interests: None declared.

References


